Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study

Mami Uchida, Hitoshi Kawazoe, Shingo Takatori, Hiroyuki Namba, Ryuji Uozumi, Akihiro Tanaka, Hiromu Kawasaki, Hiroaki Araki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Oxaliplatin-induced peripheral neuropathy has remained an unresolved issue in clinical practice. Our previous study hypothesized that inhibition of the renin-angiotensin system (RAS) may produce a preventive effect on oxaliplatin-induced neuropathy. The aim of this study was to clarify whether RAS inhibitors prevent oxaliplatin-induced peripheral neuropathy. Methods: This study retrospectively analyzed data from cancer patients who had received chemotherapy including oxaliplatin and were treated with or without RAS inhibitors. This retrospective observational study was conducted at Ehime University Hospital using electronic medical records from May 2009 to December 2016. The primary end point was the incidence of severe peripheral neuropathy during or after oxaliplatin treatment, according to the Common Terminology Criteria for Adverse Events, version 4.0. A multivariate Cox proportional hazards model analysis was used to identify risk factors. Findings: A total of 150 patients were included in the study. The estimated incidence of peripheral neuropathy was 36.9% and 91.7% in the RAS inhibitor group and the non–RAS inhibitor group, respectively. The multivariate analysis using a Cox proportional hazards model showed that the RAS inhibitor group was slightly associated with a decreased risk of neurotoxicity (adjusted hazard ratio, 0.42 [95% CI, 0.18–0.99]; P = 0.048). Implications: The present findings suggest that RAS inhibitors have the ability to prevent oxaliplatin-induced peripheral neuropathy.

Original languageEnglish
JournalClinical Therapeutics
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Renin-Angiotensin System
Observational Studies
Retrospective Studies
Proportional Hazards Models
Electronic Health Records
Incidence
Terminology
Multivariate Analysis

Keywords

  • angiotensin receptor blocker
  • angiotensin-converting enzyme inhibitor
  • chemotherapy-induced peripheral neuropathy
  • oxaliplatin
  • renin-angiotensin system inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy : A Retrospective Observational Study. / Uchida, Mami; Kawazoe, Hitoshi; Takatori, Shingo; Namba, Hiroyuki; Uozumi, Ryuji; Tanaka, Akihiro; Kawasaki, Hiromu; Araki, Hiroaki.

In: Clinical Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Uchida, Mami ; Kawazoe, Hitoshi ; Takatori, Shingo ; Namba, Hiroyuki ; Uozumi, Ryuji ; Tanaka, Akihiro ; Kawasaki, Hiromu ; Araki, Hiroaki. / Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy : A Retrospective Observational Study. In: Clinical Therapeutics. 2018.
@article{065cd6f8e8d544d8964e68b2fba91b54,
title = "Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study",
abstract = "Purpose: Oxaliplatin-induced peripheral neuropathy has remained an unresolved issue in clinical practice. Our previous study hypothesized that inhibition of the renin-angiotensin system (RAS) may produce a preventive effect on oxaliplatin-induced neuropathy. The aim of this study was to clarify whether RAS inhibitors prevent oxaliplatin-induced peripheral neuropathy. Methods: This study retrospectively analyzed data from cancer patients who had received chemotherapy including oxaliplatin and were treated with or without RAS inhibitors. This retrospective observational study was conducted at Ehime University Hospital using electronic medical records from May 2009 to December 2016. The primary end point was the incidence of severe peripheral neuropathy during or after oxaliplatin treatment, according to the Common Terminology Criteria for Adverse Events, version 4.0. A multivariate Cox proportional hazards model analysis was used to identify risk factors. Findings: A total of 150 patients were included in the study. The estimated incidence of peripheral neuropathy was 36.9{\%} and 91.7{\%} in the RAS inhibitor group and the non–RAS inhibitor group, respectively. The multivariate analysis using a Cox proportional hazards model showed that the RAS inhibitor group was slightly associated with a decreased risk of neurotoxicity (adjusted hazard ratio, 0.42 [95{\%} CI, 0.18–0.99]; P = 0.048). Implications: The present findings suggest that RAS inhibitors have the ability to prevent oxaliplatin-induced peripheral neuropathy.",
keywords = "angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, chemotherapy-induced peripheral neuropathy, oxaliplatin, renin-angiotensin system inhibitors",
author = "Mami Uchida and Hitoshi Kawazoe and Shingo Takatori and Hiroyuki Namba and Ryuji Uozumi and Akihiro Tanaka and Hiromu Kawasaki and Hiroaki Araki",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clinthera.2018.05.011",
language = "English",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",

}

TY - JOUR

T1 - Preventive Effects of Renin-Angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy

T2 - A Retrospective Observational Study

AU - Uchida, Mami

AU - Kawazoe, Hitoshi

AU - Takatori, Shingo

AU - Namba, Hiroyuki

AU - Uozumi, Ryuji

AU - Tanaka, Akihiro

AU - Kawasaki, Hiromu

AU - Araki, Hiroaki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Oxaliplatin-induced peripheral neuropathy has remained an unresolved issue in clinical practice. Our previous study hypothesized that inhibition of the renin-angiotensin system (RAS) may produce a preventive effect on oxaliplatin-induced neuropathy. The aim of this study was to clarify whether RAS inhibitors prevent oxaliplatin-induced peripheral neuropathy. Methods: This study retrospectively analyzed data from cancer patients who had received chemotherapy including oxaliplatin and were treated with or without RAS inhibitors. This retrospective observational study was conducted at Ehime University Hospital using electronic medical records from May 2009 to December 2016. The primary end point was the incidence of severe peripheral neuropathy during or after oxaliplatin treatment, according to the Common Terminology Criteria for Adverse Events, version 4.0. A multivariate Cox proportional hazards model analysis was used to identify risk factors. Findings: A total of 150 patients were included in the study. The estimated incidence of peripheral neuropathy was 36.9% and 91.7% in the RAS inhibitor group and the non–RAS inhibitor group, respectively. The multivariate analysis using a Cox proportional hazards model showed that the RAS inhibitor group was slightly associated with a decreased risk of neurotoxicity (adjusted hazard ratio, 0.42 [95% CI, 0.18–0.99]; P = 0.048). Implications: The present findings suggest that RAS inhibitors have the ability to prevent oxaliplatin-induced peripheral neuropathy.

AB - Purpose: Oxaliplatin-induced peripheral neuropathy has remained an unresolved issue in clinical practice. Our previous study hypothesized that inhibition of the renin-angiotensin system (RAS) may produce a preventive effect on oxaliplatin-induced neuropathy. The aim of this study was to clarify whether RAS inhibitors prevent oxaliplatin-induced peripheral neuropathy. Methods: This study retrospectively analyzed data from cancer patients who had received chemotherapy including oxaliplatin and were treated with or without RAS inhibitors. This retrospective observational study was conducted at Ehime University Hospital using electronic medical records from May 2009 to December 2016. The primary end point was the incidence of severe peripheral neuropathy during or after oxaliplatin treatment, according to the Common Terminology Criteria for Adverse Events, version 4.0. A multivariate Cox proportional hazards model analysis was used to identify risk factors. Findings: A total of 150 patients were included in the study. The estimated incidence of peripheral neuropathy was 36.9% and 91.7% in the RAS inhibitor group and the non–RAS inhibitor group, respectively. The multivariate analysis using a Cox proportional hazards model showed that the RAS inhibitor group was slightly associated with a decreased risk of neurotoxicity (adjusted hazard ratio, 0.42 [95% CI, 0.18–0.99]; P = 0.048). Implications: The present findings suggest that RAS inhibitors have the ability to prevent oxaliplatin-induced peripheral neuropathy.

KW - angiotensin receptor blocker

KW - angiotensin-converting enzyme inhibitor

KW - chemotherapy-induced peripheral neuropathy

KW - oxaliplatin

KW - renin-angiotensin system inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85049303459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049303459&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2018.05.011

DO - 10.1016/j.clinthera.2018.05.011

M3 - Article

C2 - 29983264

AN - SCOPUS:85049303459

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

ER -